Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Everolimus (0.25mg) Tablet
Therapeutic Category
Immunology, Oncology
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Everloop 0.25 Tablet contains Everolimus 0.25 mg, an mTOR inhibitor with potent immunosuppressive and antiproliferative properties. It is widely used in organ transplant patients to prevent rejection and in selected oncology indications where controlled inhibition of cell growth is required.
Everolimus works by blocking the mammalian target of rapamycin (mTOR) pathway, thereby suppressing T-cell activation and reducing abnormal cell proliferation. This mechanism helps in maintaining graft survival while minimizing immune-mediated damage.
Clinically, Everloop 0.25 Tablet is prescribed for post-transplant immunosuppression and specific tumor-related therapies, often as part of combination treatment protocols under strict medical supervision.
The tablet offers precise low-dose control, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospital use, transplant centers, and specialized clinical settings requiring long-term immune modulation.
Common side effects may include mouth ulcers, infections, fatigue, rash, diarrhea, nausea, and increased blood lipid levels. Rarely, serious effects such as impaired wound healing, lung toxicity, severe infections, or blood count abnormalities may occur.
Everloop 0.25 Tablet is indicated for the prevention of organ transplant rejection in combination with other immunosuppressants. It is also used in the treatment of specific cancers and benign tumors, such as renal cell carcinoma, neuroendocrine tumors, and tuberous sclerosis complex–associated conditions, as prescribed by a specialist.
Use Everloop 0.25 Tablet strictly under specialist supervision. Regular monitoring of blood counts, kidney function, lipid profile, and drug levels may be required. Inform your doctor if you have active infections, liver impairment, or are taking other immunosuppressive medicines. Avoid live vaccines during therapy and seek immediate medical attention if signs of infection or breathing difficulty occur.
Store below 25°C in a dry place. Protect from light and moisture. Keep out of reach of children. Do not use beyond the expiry date.
Composition : Deflazacort (18mg) Tablet
Composition : Deflazacort (30mg)
Composition : Deflazacort (6mg)
Composition : Methylprednisolone (8mg)
Composition : Methylprednisolone (4mg)
Composition : Methylprednisolone (16mg)
Composition : Deflazacort (6mg/5ml)
Composition : Deflazacort (6mg/5ml) Suspension
Composition : Methylprednisolone (1000mg) Injection
Composition : Methylprednisolone (125mg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Everolimus 0.25mg Tablet is an immunosuppressant and targeted therapy medicine used in organ transplantation and oncology treatments, making it a highly specialized hospital and specialty-care product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in transplant care, oncology departments, and specialty hospitals. It is commonly prescribed by oncologists and transplant specialists for long-term treatment protocols, ensuring stable institutional demand.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Everolimus 0.25mg Tablet with monopoly rights, specialty-care manufacturing standards, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from high-value prescriptions, long-term therapy cycles, and steady hospital procurement in oncology and transplant segments when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this specialty-care formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.